Celgene Corp. (CELG)

93.47
NASDAQ : Health Technology
Prev Close 98.91
Day Low/High 93.47 / 95.80
52 Wk Low/High 58.59 / 98.97
Avg Volume 6.64M
Exchange NASDAQ
Shares Outstanding 705.26M
Market Cap 69.76B
EPS 5.70
P/E Ratio 15.10
Div & Yield N.A. (N.A)
Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

Who Will Win This Game of 'World of Trade Warcraft,' the U.S. or China?

The Chinese have something to lose here, and will not willingly surrender their position of superiority in trade.

Busy Day on Tap: Look for a Solid Jobs Number

It is good once again to be sitting in for Doug Kass on a Friday here on the Daily Diary. Going to be a busy day as we get the monthly jobs report coming out in just over an hour. Although GDP growth (2.3%) did slow in the first quarter from the 3% ...

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Markets Struggle to Find Direction

Markets continue to meander between being slightly up or slightly down as equities struggle for a direction after yesterday's big slide. New homes sales for the month of February were above expectations with the average selling price 10% above the s...

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Celgene Showing a Bullish Divergence But Is Still In a Downtrend

Let's check the charts.

Which Hot Biotech Name Will Be Acquired Next?

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.

Bret Jensen's Biotech Mailbag

Bret Jensen's Biotech Mailbag

We'll answer two of the common questions we have received so far in March.

3 Promising Biotech Stocks to Buy on Dips

3 Promising Biotech Stocks to Buy on Dips

From ANI Pharmaceuticals to T2 Biosystems, these names look good.

Three Biotech Opportunities

Three Biotech Opportunities

Celgene, ANI and T2 are seeing attractive entry points.

Multiple Creep... and More

Recently I have noticed some of Wall Street's younger analysts engaging in "multiple creep." They seem to be treating a 12 EBITD (cash flow) multiple like a 12 PE (price to earnings) ratio. Whoops! No problem, for example, paying 25x EPS for ....Unt...

Three Stocks That Have My Attention

Three Stocks That Have My Attention

I continue to deploy some of the 'dry powder' into the market after its recent hiccup.

Cramer: 10 Stock Surprises

Cramer: 10 Stock Surprises

In this tape, weakness may just be a sign of rest and better times to come.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Tax Reform's Impact on the Economy

Tax Reform's Impact on the Economy

Consumer spending should be more than solid given wage increases.

Closing Bell: LIVE MARKETS BLOG

Closing Bell: LIVE MARKETS BLOG

All three indices closed the day in record territory.

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

Video: Jim Cramer on the Eagles, Celgene, Juno Therapeutics and Netflix

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Monday's trending topics.

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

Video: Jim Cramer Reacts to Celgene's Plans to Acquire Juno Therapeutics

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts to Celgene's plans to acquire Juno Therapeutics for about $9 billion on Monday.

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

A Government Shutdown Won't Crush Stock Market, a New England Patriots Win Will

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?

M&A Rumors Rise Again

About a half hour to go before the markets open for the last trading day of the week. Acorda Therapeutics is up more than 10% in pre-market trading on rumors it could be the target of several potential suitors, including Biogen . Juno Therapeutics h...

Reversal Offers Chance in 2 Small Biotechs

Reversal Offers Chance in 2 Small Biotechs

I've added to my positions in these names on yesterday's intraday silliness.

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin, Celgene and Everything Else You Need to Before Wednesday's Opening Bell

Bitcoin maintains its decline while U.S. stock futures suggest a rebound from yesterday's small loss. Are you ready for today's trading?

Celegene, CES and Everything Else You Need to Know Monday in Under 60 Seconds

Celegene, CES and Everything Else You Need to Know Monday in Under 60 Seconds

Are you ready to start the week? Here's what needs to be on your radar.

Some Morning Observations

So far: * Retail is quickly reversing yesterdays strength. Dillard's (-$1.70) and Macy's (-$0.70) downside leaders. * Gold quiet, +$1.90. Though optimistic for the full year I would not chase SPDY Gold ETF GLD at these levels. (I am a buyer on weakn...

Jim Cramer: Stocks Are on Fire For Good Reasons

Jim Cramer: Stocks Are on Fire For Good Reasons

Stocks put in broad gains supported by tax cuts, bonuses, a weaker dollar and more.

Use Caution on Celgene, Going Long Is for the Aggressive and Experienced

Use Caution on Celgene, Going Long Is for the Aggressive and Experienced

This is the kind of activity you see at a climax low.